Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.
Back
Post-Conference Perspectives: Uveal Melanoma
Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.
Post-Conference Perspectives: Uveal Melanoma
Episodes
All
All
Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.
Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.
Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Advertisement
Advertisement
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
3
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5